Region:Middle East
Author(s):Geetanshi
Product Code:KRAE1922
Pages:99
Published On:February 2026

By Type:The genetic testing market can be segmented into various types, including diagnostic testing, predictive testing, carrier testing, prenatal testing, newborn screening, pharmacogenomic testing, and others. Each of these sub-segments plays a crucial role in addressing specific healthcare needs, with diagnostic testing being the most prominent due to its direct application in disease identification and management.

By End-User:The end-user segmentation includes hospitals, diagnostic laboratories, research institutions, direct-to-consumer services, and others. Hospitals are the leading end-users due to their comprehensive healthcare services and the need for genetic testing in patient management and treatment planning.

The Oman Genetic Testing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Sultan Qaboos University Hospital, Oman Medical Specialty Board, Al Nahda Hospital, Muscat Private Hospital, Aster DM Healthcare, Oman Medical Laboratory, Al Hayat International Hospital, Badr Al Samaa Hospital, Dr. Ahmed Al Shukaili Clinic, Oman Genetic Center, Al Noor Hospital, Muscat Genetics, Oman Health Services, Gulf Medical University, Oman Biotechnology Company contribute to innovation, geographic expansion, and service delivery in this space.
The future of the Oman genetic testing market appears promising, driven by increasing healthcare investments and a growing emphasis on preventive medicine. As the government allocates more resources to healthcare, the establishment of new testing facilities is anticipated. Additionally, the integration of telehealth services is expected to enhance access to genetic counseling, making testing more convenient for patients. These developments will likely foster a more robust genetic testing ecosystem in Oman, addressing both current challenges and future demands.
| Segment | Sub-Segments |
|---|---|
| By Type | Diagnostic Testing Predictive Testing Carrier Testing Prenatal Testing Newborn Screening Pharmacogenomic Testing Others |
| By End-User | Hospitals Diagnostic Laboratories Research Institutions Direct-to-Consumer Others |
| By Application | Oncology Cardiovascular Diseases Neurological Disorders Rare Diseases Others |
| By Technology | Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Microarray Sanger Sequencing Others |
| By Sample Type | Blood Samples Saliva Samples Tissue Samples Others |
| By Region | Muscat Dhofar Al Batinah Al Dakhiliyah Others |
| By Policy Support | Government Grants Tax Incentives Research Funding Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Healthcare Providers | 100 | Geneticists, Oncologists, Family Physicians |
| Laboratory Technicians | 80 | Laboratory Managers, Genetic Testing Technicians |
| Patients and Families | 75 | Individuals who have undergone genetic testing, Caregivers |
| Healthcare Policy Makers | 50 | Health Ministry Officials, Public Health Experts |
| Insurance Providers | 60 | Health Insurance Underwriters, Claims Adjusters |
The Oman Genetic Testing Market is valued at approximately USD 12 million, reflecting a significant growth driven by increased awareness of genetic disorders, advancements in technology, and the rising prevalence of chronic diseases.